Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio
Abstract
One hundred one patients with coronary artery disease and pretreatment ratios of total cholesterol to high density lipoprotein (HDL) cholesterol greater than 4.0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily. Dosage adjustments were made to minimize side effects. At a mean follow-up duration of 11 +/- 7 months, and a mean dosage of 1,415 +/- 698 mg/day, the group had a 13% reduction in total cholesterol, 31% increase in HDL and 32% decrease in the cholesterol to HDL ratio. A subgroup of 62 patients taking greater than 1,000 mg/day of niacin had an 18% reduction in total cholesterol, 32% increase in HDL and 36% improvement in the cholesterol to HDL ratio. A subgroup of 39 patients taking less than or equal to 1,000 mg/day of niacin had only a 5% reduction in total cholesterol, although a 29% increase in HDL and a 24% decrease in the cholesterol to HDL ratio were recorded. Side effects of niacin were reported in 38% of the patients, but led to discontinuation of therapy in only 4. Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fibrates activate PPARα, a nuclear receptor, by binding as ligands.
“Their primary mechanism of action is the activation of PPARα, a nuclear receptor, through binding of fibrates as ligands686, 687).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [686]
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059 · see citing works
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · see citing works
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621 · see citing works
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,292 · see citing works
CORONARY HEART DISEASE IN SEVEN COUNTRIES
(1971) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1971.tb50629.x · Cited by 1,848 · see citing works
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · see citing works
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750 · see citing works
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654 · see citing works
The Lipid Research Clinics Coronary Primary Prevention Trial Results
(1984) · JAMA · doi:10.1001/jama.1984.03340270043026 · Cited by 1,402 · see citing works
Cholesterol in the Prediction of Atherosclerotic Disease
Kannel, W. B., Castelli, W. P., & Gordon, T. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-85 · Cited by 1,314 · see citing works
Miller, N. E., Thelle, D. S., Førde, O. H., & Mjøs, O. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92274-7 · Cited by 1,206 · see citing works
The Pooling Project Research Group (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90073-5 · Cited by 994 · see citing works
ISCHÆMIC HEART-DISEASE IN RELATION TO FASTING VALUES OF PLASMA TRIGLYCERIDES AND CHOLESTEROL
Carlson, L., & Böttiger, L. E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90738-6 · Cited by 752 · see citing works
Diet, Serum Cholesterol, and Death from Coronary Heart Disease
Shekelle, R. B., Shryock, A. M., Paul, O., Lepper, M. H., Stamler, J., Liu, S., & Raynor, W. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101083040201 · Cited by 714 · see citing works
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 498 · see citing works
Levy, R. I., Brensike, J. F., Epstein, S. E., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., & Battaglini, J. W. (1984) · Circulation · doi:10.1161/01.cir.69.2.325 · Cited by 437 · see citing works
Carlson, L. A., & Orö, L. (1962) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1962.tb07203.x · Cited by 434 · see citing works
High Density Lipoprotein Metabolism in Man
Blum, C. B., Levy, R. I., Eisenberg, S., Hall, M., Goebel, R. H., & Berman, M. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108833 · Cited by 406 · see citing works
ROBERTSON, T. L., Kato, H., Rhoads, G. G., Kagan, A., Marmot, M. G., Syme, S. L., Gordon, T., Worth, R. M., Belsky, J. L., Dock, D. S., et al. (1977) · The American Journal of Cardiology · doi:10.1016/s0002-9149(77)80197-5 · Cited by 314 · see citing works
Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
Grundy, S. M., Mok, H. Y. I., Zech, L. A., & Berman, M. D. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34737-4 · Cited by 270 · see citing works
Shepherd, J., Packard, C. J., Patsch, J. R., Gotto, A. M., & Taunton, O. D. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109385 · Cited by 248 · see citing works
Predicting coronary heart disease in middle-aged and older persons. The Framington study
Gordon, T. (1977) · JAMA · doi:10.1001/jama.238.6.497 · Cited by 239 · see citing works
Metabolic effects of nicotinic acid and its derivatives
GEY, K. F., & Carlson, B. A. (1971) · Medical Entomology and Zoology · Cited by 216 · see citing works
Gass, J. D. M. (1973) · American Journal of Ophthalmology · doi:10.1016/0002-9394(73)90738-1 · Cited by 112 · see citing works
Malloy, M. J., KANE, J. P., KUNITAKE, S. T., & TUN, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-616 · Cited by 87 · see citing works
Hoeg, J. M., Maher, M. B., Bou, E., Zech, L. A., Bailey, K. R., Gregg, R. E., Sprecher, D. L., SUSSER, J. K., Pikus, A., & Brewer, H. B. (1984) · Circulation · doi:10.1161/01.cir.70.6.1004 · Cited by 38 · see citing works
Uhl, G. S., Troxler, R. G., Hickman, J. R., & Clark, D. A. (1981) · The American Journal of Cardiology · doi:10.1016/0002-9149(81)90357-x · Cited by 35 · see citing works
Current pharmacologic treatment of elevated serum cholesterol.
Tikkanen, M. J., & Nikkilä, E. (1987) · Circulation · doi:10.1161/01.cir.76.3.529 · Cited by 33 · see citing works
Jaundice due to nicotinic acid therapy
Einstein, N., Baker, A. L., Galper, J., & Wolfe, H. J. (1975) · Digestive Diseases and Sciences · doi:10.1007/bf01070732 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works
Safety of high-dose nicotinamide: a review
Knip, M., Douek, I. F., Moore, W. P. T., Gillmor, H. A., McLean, A. E. M., Bingley, P. J., & Gale, E. A. M. (2000) · Diabetologia · doi:10.1007/s001250051536 · Cited by 423 · see citing works
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works
McKenney, J. M. (1994) · JAMA · doi:10.1001/jama.1994.03510330050033 · Cited by 303 · see citing works
Hyperlipidemia and Diabetes Mellitus
O’Brien, T., Nguyen, T. T., & Zimmerman, B. R. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.10.969 · Cited by 203 · see citing works
Ashen, M. D., & Blumenthal, R. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp044370 · Cited by 168 · see citing works
The antiatherogenic role of high-density lipoprotein cholesterol
Kwiterovich, P. O. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00808-x · Cited by 160 · see citing works
Morgan, J. M., Capuzzi, D. M., & Guyton, J. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00732-2 · Cited by 139 · see citing works
Morgan, J. M., Capuzzi, D. M., Guyton, J. R., Centor, R. M., Goldberg, R. B., Robbins, D. C., DiPette, D. J., Jenkins, S. H., & Marcovina, S. M. (1996) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849600100302 · Cited by 114 · see citing works
DiPalma, & THAYER, W. S. (1991) · Annual Review of Nutrition · doi:10.1146/annurev.nu.11.070191.001125 · Cited by 106 · see citing works
Brown, B. G., Bardsley, J., Poulin, D., Hillger, L. A., Dowdy, A. A., Maher, V. M. G., Zhao, X.-Q., Albers, J. J., & Knopp, R. H. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00303-2 · Cited by 102 · see citing works
Goldberg, R., & Roth, D. (1996) · Transplantation · doi:10.1097/00007890-199612150-00005 · Cited by 85 · see citing works
High-Density Lipoprotein Cholesterol and Coronary Heart Disease
Young, C. E., Karas, R. H., & Kuvin, J. T. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000097140.29929.8a · Cited by 84 · see citing works
Meyers, C. D., Carr, M. C., Park, S., & Brunzell, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-12-200312160-00009 · Cited by 72 · see citing works
Vega, G. L. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420010101012 · Cited by 63 · see citing works
King, J. M., Crouse, J. R., Terry, J. G., Morgan, T. M., Spray, B. J., & Miller, N. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90298-4 · Cited by 53 · see citing works
Drug treatment of dyslipoproteinemia
Larsen, M. L., & Illingworth, D. R. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30184-5 · Cited by 49 · see citing works
Schectman, G., Hiatt, J. G., & Hartz, A. J. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90820-3 · Cited by 49 · see citing works
Tatò, F., Vega, G. L., & Grundy, S. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)01016-3 · Cited by 48 · see citing works
Keenan, J. M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.7.1424 · Cited by 48 · see citing works
Raising HDL cholesterol in women
Merchant, N. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5110 · Cited by 48 · see citing works
Lipid management: current diet and drug treatment options.
Stone, N. (1996) · American Journal of Medicine · doi:10.1016/s0002-9343(96)00319-1 · Cited by 52 · see citing works
Jacobson, T. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0535 · Cited by 41 · see citing works
Martı́n-Jadraque, R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00040041081006 · Cited by 40 · see citing works
Current perspectives on the management of hypertriglyceridemia
Miller, M. J. (2000) · American Heart Journal · doi:10.1067/mhj.2000.108001 · Cited by 40 · see citing works
Telephone Contacts Do Not Improve Adherence to Niacin or Bile Acid Sequestrant Therapy
Schectman, G., Hiatt, J., & Hartz, A. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800104 · Cited by 39 · see citing works
Boyonoski, A. C., Spronck, J. C., Kirkland, J. B., Jacobs, R. M. J., Shah, G. M., & Poirier, G. G. (2002) · Journal of Nutrition · doi:10.1093/jn/132.1.115 · Cited by 38 · see citing works
Drug Treatment of Dyslipoproteinemia
Hunninghake, D. B. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30329-3 · Cited by 35 · see citing works
Nicotinic Acid for the Treatment of Hyperlipoproteinemia
Drood, J. M., ZIMETBAUM, P. J., & Frishman, W. H. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03750.x · Cited by 33 · see citing works
How Well Tolerated Are Lipid-Lowering Drugs?
Tomlinson, B., Chan, P., & Lan, W. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00003 · Cited by 31 · see citing works
O’Brien, T., SILVERBERG, J. D., & Nguyen, T. T. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60393-0 · Cited by 26 · see citing works
Residual risk in statin-treated patients: Future therapeutic options
Campbell, C. Y., Rivera, J. J., & Blumenthal, R. S. (2007) · Current Cardiology Reports · doi:10.1007/bf02938395 · Cited by 25 · see citing works
Wink, J. S., Giacoppe, G. N., & King, J. (2002) · American Heart Journal · doi:10.1067/mhj.2002.120158 · Cited by 25 · see citing works
Raising an isolated low HDL-C level: why, how, and when?
Miller, M. J. (2003) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.70.6.553 · Cited by 21 · see citing works
Goerdt, C. J., Keith, M., & Bloomfield, H. E. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04118.x · Cited by 21 · see citing works
Keenan, J. M., Bae, C., Fontaine, P. L., Wenz, J. B., Myers, S., Huang, Z., & Ripsin, C. M. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01822.x · Cited by 19 · see citing works
Vitamin supplements: current controversies.
Reynolds, R. D. (1994) · Journal of the American College of Nutrition · doi:10.1080/07315724.1994.10718383 · Cited by 18 · see citing works
Nicotinic Acid as a Lipoprotein-Altering Agent
Probstfield, J. L. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420140015002 · Cited by 18 · see citing works
Squires, R. W., Allison, T. G., Gau, G. T., Miller, T. D., & Kottke, B. A. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60824-6 · Cited by 17 · see citing works
Treating Hyperlipidemia in the Elderly
Fleming, R. M., Ketchum, K. L., Fleming, D. M., & Gaede, R. (1995) · Angiology · doi:10.1177/000331979504601202 · Cited by 16 · see citing works
Majeed, F., & Miller, M. J. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f79b0b · Cited by 16 · see citing works
Effects of niacin on biliary lipid output in the rat
Holland, R. E., Rahman, K., Morris, A. I., COLEMAN, R., & Billington, D. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90375-7 · Cited by 16 · see citing works
Assessing the Independent Effect of Dietary Counseling and Hypolipidemic Medications on Serum Lipids
Fleming, R. M., Ketchum, K. L., Fleming, D. M., & Gaede, R. (1996) · Angiology · doi:10.1177/000331979604700901 · Cited by 15 · see citing works
High-Density Lipoprotein Cholesterol-Raising Strategies
Kuvin, J. T., Alsheikh-Ali, A. A. A., & Karas, R. H. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000199684.20578.7c · Cited by 14 · see citing works
Patient-Directed, Nonprescription Approaches to Cardiovascular Disease
Simon, H. B. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.20.2283 · Cited by 14 · see citing works
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19166 · Cited by 13 · see citing works
Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia
Schmidt, D. R., Smenton, A. L., Raghavan, S., Carballo‐Jane, E., Lubell, S., Ciecko, T., Holt, T. G., Wolff, M., Taggart, A. K. P., Wilsie, L. C., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.054 · Cited by 13 · see citing works
Ahmadi, F., Lessan-Pezeshki, M., Shamekhi, F., & Khatami, M. (2012) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.100865 · Cited by 13 · see citing works
Unstable myocardial ischemia after the initiation of niacin therapy
Pasternak, R. C., & Kolman, B. S. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90631-t · Cited by 12 · see citing works
Self-citationEffect of a Combination of Gemfibrozil and Niacin on Lipid Levels
Spencer, G. A., Wirebaugh, S. R., & Whitney, E. J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04237.x · Cited by 12 · see citing works
Brown, W. V. (1995) · Postgraduate Medicine · doi:10.1080/00325481.1995.11946037 · Cited by 11 · see citing works
A clinical trial of oat bran and niacin in the treatment of hyperlipidemia.
Keenan, J. M., Wenz, J. B., Ripsin, C. M., Huang, Z., & McCaffrey, D. J. (1992) · PubMed · Cited by 11 · see citing works
Response of Laying Hens to Supplemental Niacin
Leeson, S., Caston, L. J., & SUMMERS, J. D. (1991) · Poultry Science · doi:10.3382/ps.0701231 · Cited by 10 · see citing works
Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience
Luria, M. H., & Sapoznikov, D. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.810.296 · Cited by 8 · see citing works
Keenan, J. M. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.10.004 · Cited by 8 · see citing works
Drug therapy of hyperlipidemia
Prihoda, J. S., & Illingworth, D. R. (1992) · Current Problems in Cardiology · doi:10.1016/0146-2806(92)90004-8 · Cited by 7 · see citing works
Combination drug therapy in the treatment of severe hyperlipidaemia
Contermans, J., & Erkelens, D. W. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90160-i · Cited by 5 · see citing works
McKenney, J. M. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.9.1781 · Cited by 5 · see citing works
Teramoto, T., Sasaki, J., Ueshima, H., Egusa, G., Kinoshita, M., Shimamoto, K., Daida, H., Biro, S., Hirobe, K., Funahashi, T., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e619 · Cited by 4 · see citing works
Kirkland, J. B. (2007) · CRC Press eBooks · doi:10.1201/9781420005806.ch6 · Cited by 4 · see citing works
Cholesterol, Triglycerides, and the Treatment of Hyperlipidemias
Fleming, R. M. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1190-7_30 · Cited by 2 · see citing works
Yeh, Y., Lee, Y.-T., & Hwang, D. (2007) · 中醫藥雜誌 · Cited by 2 · see citing works
Safety and side effects of sustained-release niacin
Keenan, J. M. (1994) · JAMA · doi:10.1001/jama.272.7.513b · Cited by 2 · see citing works
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Parhofer, K., Richter, W., & Schwandt, P. (1996) · Artificial Organs · doi:10.1111/j.1525-1594.1996.tb04446.x
Hypercholesterolemia: Whom and How to Treat
(1990) · New England Journal of Medicine · doi:10.1056/nejm199003083221012 · Cited by 1 · see citing works
Use of Lipid‐Lowering Agents in the Prevention of Cardiovascular Disease
Failor, R. A., & Probstfield, J. L. (2009) · doi:10.1002/9781444309768.ch12
New trends in lipidology: the increasing role of HDL-cholesterol
Paragh, G., Harangi, M., & Márk, L. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28405
Shil, A. B. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03696.x
ARBITER 6-HALTS. Does it have the power to settle all matters?
Ferrario, C. M. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709359518
Gracheva, I. N., Orekhova, E. M., Kopelevich, V. M., Tyurenkov, I. N., Kleshchitskii, B. A., & Швец, В. И. (1996) · Pharmaceutical Chemistry Journal · doi:10.1007/bf02219682
Gandotra, P., & Miller, M. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00013-5
Henkin, Y. (1990) · JAMA · doi:10.1001/jama.1990.03450230026018
Raghuwanshi, P. K. P., Rastogi, A. L. K. A., Singh, D. C. V. P., & Wazir, S. K. V. S. (2019) · International Journal of Current Microbiology and Applied Sciences · doi:10.20546/ijcmas.2019.808.118
Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease
Probstfield, J. L. (2002) · doi:10.1002/9780470986882.ch13
Heath, E. M. (2005) · Nutrition in exercise and sport · doi:10.1201/9781420037913.ch5
The Future of Brain Protection: Natural Alternatives
Maynard, K. I. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0282-1_6
Reuter, H. D. (1992) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80520-3
Teramoto, T., Matsushima, T., Watanabe, T., Yamada, N., ISHIBASHI, S., Shimano, H., Itakura, H., Saitō, Y., Shirai, K., Morisaki, N., et al. (1991) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.19.2-3_199
BindingDB (2012) · UC San Diego · doi:10.7270/q2m909m3
- Authors
- Alderman, J. D., Pasternak, R. C., Sacks, F. M., Smith, H. S., Monrad, E. S., & Grossman, W.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Pasternak, Richard C.
- ORCID
- Sacks, Frank M.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1989-10
- Volume
- 64
- Issue
- 12
- Pages
- 725-729
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2072615103
- Cited by
- 80
- References
- 30
- Citations by year
- 2023: 1 · 2019: 1 · 2018: 1 · 2013: 1 · 2012: 2
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nicotinic acid, TC/HDL-C ratio, HDL cholesterol, total cholesterol, coronary artery disease, lipid-lowering therapy
- MeSH terms
- Adult, Aged, Cholesterol, Coronary Disease, Female, Humans, Lipoproteins, HDL, Cholesterol, HDL, Male, Middle Aged, Niacin, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review